MKI67 and metastatic malignant neoplasm: In line with our previous findings, pharmacological inhibition of AXL after gemcitabine withdrawal significantly reduced metastatic relapse (figure 6L; online supplemental figure S8A, B), AXL (pAXL) activation and proliferation (Ki67+) of metastatic cancer cells (figure 6M–P), while immune cell infiltration remained unaffected (online supplemental figure S8C–G).